Navigation Links
Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
Date:10/25/2013

Irvine, CA (PRWEB) October 25, 2013

Proove Biosciences, the leading personalized pain medicine laboratory, is excited to be presenting clinical data on how its genetic testing services have been helping doctors better prescribe pain medication at the 2013 Common Sense Pain Management Conference. The event will take place October 25th and 26th at the Renaissance Orlando Airport Hotel, in Orlando, Florida.

This industry CME course, a collaborative partnership between the Florida Medical Association, Florida Academy of Pain Medicine, Florida Society of Interventional Pain Physicians, and Florida Society of Physical Medicine and Rehabilitation, will help attendees and physicians adopt a common sense approach to pain management and controlled substance prescribing practices.

Topics and faculty of the program have been selected to ensure attendees will be better equipped to navigate changing regulations in this complex field. Proove Biosciences Medical Advisory Board member, Andrea Trescot, will present information on how genetic testing for narcotic risk and drug metabolism helps physicians meet new prescribing challenges through practice-based evidence at a dinner event hosted by the program’s organizers on Friday, October 25, 2013.

“We are excited for the opportunity to present our clinical data and research at the Common Sense Pain Management CME course,” stated Proove Biosciences President and Founder, Brian Meshkin. “As the only company who continues to present research on the genetics of pain medicine and as the only company offering proprietary testing servi
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree
2. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
3. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
4. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
5. Sangamo BioSciences Reports Third Quarter 2013 Financial Results
6. Rancho BioSciences will present the tranSMART open source platform at TM Forum’s Digital Disruption 2013, Oct 28-31, San Jose
7. Jeeven BioSciences, Inc. Announces the Release of Its Neuro-XTM Serum-Free and Xeno-Free Tissue Culture Media
8. Castle Biosciences Launches Tissue Repository for Eye Cancer Patients
9. Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo
10. MD Biosciences Publishes the Characterization of a Porcine Model of Post-operative Or Incisional Pain in the European Journal of Pain
11. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea ... new development in Downtown Toronto is expanding at a ... 755 storeys of new development last week (including three ... dominating the Toronto skyline for the foreseeable future in ... for new development. , As the Toronto city council ...
(Date:9/15/2014)... phase transitionsthink solid, liquid, and gasbut much ... drops. If phase transitions occur at the ... subtle fluctuations can dramatically transform a material. ... of Energy,s Brookhaven National Laboratory and Stony ... of absolute zero to isolate and probe ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... Calif. , Sept. 15, 2014  FlexTech ... (RFP) for flexible, printed product demonstrators (demos) and ... two-stage RFP process with pre-proposals due on October ... 2015.  Funds for proposals ultimately selected are provided ... have a significant cost share by the proposing ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2
... Thermo Fisher,Scientific Inc. (NYSE: TMO ) announced ... president and chief executive,officer, are adopting stock- trading ... covering the future sale of company stock. Mr.,Dekkers, ... over August,15-17, 2007, has adopted a plan for ...
... Pharmion - ... - Sirtuins implicated in tumor ... combination epigenetic therapies, BOULDER, Colo. and MONTREAL, Aug. 20 ... MYG) today announced a,research collaboration for the development of novel ...
... CLAREMONT, Calif., Aug. 14 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... second quarter of 2007 increased more than,35% over the ... times,revenues of just $13,351 for the same period in ... of 2007 were $3,256,000 compared to only,$24,374 in the ...
Cached Biology Technology:Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 3Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 4Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 5Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 6Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6
(Date:9/16/2014)... us sick can take up residence in and on ... other troublesome symptom, according to new research at Washington ... On average, healthy individuals carry about five types of ... BioMed Central Biology . The study is the ... in healthy people. , The research was conducted ...
(Date:9/16/2014)... dinosaurs 66 million years ago decimated the evergreens among ... their deciduous peers, according to a study led by ... PLOS Biology . , Applying biomechanical formulas ... of angiosperms flowering plants excluding conifers ... a diverse plant community thriving during a 2.2 million-year ...
(Date:9/16/2014)... fall marks a new school year, a new football ... Space Station. In September, SpaceX,s Dragon spacecraft is scheduled ... and investigations as part of the company,s fourth contracted ... will be the third suite of research investigations sponsored ... Space (CASIS). With the role of managing the U.S. ...
Breaking Biology News(10 mins):Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3
... sexy (especially when scientists start analyzing it), but it is ... an egg and a sperm, a whole lot of cell ... that carries a mix of genes from both parents. There ... the most fundamental and important is the transition from unfertilized ...
... new drug has been shown to improve blood flow in ... heart attacks, a Monash University study published today reveals. , ... that, in conjunction with Bayer Health Care, hopes to use ... of heart disease. , Dr. Harald Schmidt, Director of the ...
... men age 40 and older have a significantly increased ... whose fathers are younger than 30 years, according to ... General Psychiatry, one of the JAMA/Archives journals. , Autism ... patterns of behavior, according to background information in the ...
Cached Biology News:Cracking the egg 2Heart smart: new drug improves blood flow 2Older fathers more likely to have autistic children 2
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... NEW HandyStep electronic from BRAND adds ... It is the only electronic, motor-driven ... syringe tips, including BRAND PD-Tip syringe ... Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. Select ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Biology Products: